Sio Gene Therapies To Present New Data At The European Society Of Gene And Cell Therapy Virtual Congress 2021
Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that it will present new
Sio Gene Therapies Announces Dosing Of First GM1 Gangliosidosis Early Infantile Patient In Ongoing Phase 1/2 Study Of AXO-AAV-GM1 Gene Therapy
Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced dosing of the first Type
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 155 companies achieved new lows for the year.
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
Stocks That Hit 52-Week Lows On Thursday
Thursday morning, 173 companies reached new 52-week lows.
SVB Leerink Maintains Outperform on Sio Gene Therapies, Lowers Price Target to $6
SVB Leerink analyst Mani Foroohar maintains Sio Gene Therapies (NASDAQ:SIOX) with a Outperform and lowers the price target from $7 to $6.